Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) had Income from Continuous Operations of $-66.46M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-66.43M |
|
-- |
|
-- |
|
$70.56M |
|
$-70.56M |
|
$3.92M |
|
$-66.63M |
|
$-66.63M |
|
$-66.46M |
|
|
Income from Continuous Operations |
$-66.46M |
$-66.46M |
|
$-66.46M |
|
$-70.56M |
|
$-64.71M |
|
40.53M |
|
40.53M |
|
$-1.64 |
|
$-1.64 |
|
| Balance Sheet Financials | |
$77.79M |
|
$3.52M |
|
$20.38M |
|
$98.17M |
|
$10.02M |
|
-- |
|
$13.86M |
|
$23.88M |
|
$74.29M |
|
$60.00M |
|
$74.29M |
|
40.85M |
|
| Cash Flow Statement Financials | |
$-47.98M |
|
$0.42M |
|
$0.00M |
|
$112.40M |
|
$71.85M |
|
$-40.55M |
|
$0.47M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.76 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-47.56M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-89.46% |
|
-110.76% |
|
-67.70% |
|
-89.46% |
|
$1.82 |
|
$-1.17 |
|
$-1.18 |
|